EKSO (Ekso Bionics Holdings) ROCE % : -38.90% (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Ekso Bionics Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ekso Bionics Holdings's annualized ROCE % for the quarter that ended in Sep. 2024 was -38.90%.

Ekso Bionics Holdings ROCE % Historical Data

The historical data trend for Ekso Bionics Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ekso Bionics Holdings ROCE % Chart

Ekso Bionics Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-108.49

-105.61

-33.32

-40.33

-56.74

Ekso Bionics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-55.94	-57.04	-63.55	-45.78	-38.90

Ekso Bionics Holdings ROCE % Calculation

Ekso Bionics Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-14.896	/	( ( (40.903 - 9.201)	+	(28.918 - 8.117) )	/ 2 )
	=	-14.896	/	( (31.702	+	20.801)	/ 2 )
	=	-14.896	/	26.2515
	=	-56.74 %

Ekso Bionics Holdings's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-7.972	/	( ( (26.984 - 7.704)	+	(29.209 - 7.506) )	/ 2 )
	=	-7.972	/	( ( 19.28	+	21.703 )	/ 2 )
	=	-7.972	/	20.4915
	=	-38.90 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Ekso Bionics Holdings (NAS:EKSO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ekso Bionics Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Ekso Bionics Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ekso Bionics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ekso Bionics Holdings Inc (NAS:EKSO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0IFR:UK 23E2:Germany

Address

101 Glacier Point, Suite A, San Rafael, CA, USA, 94901

Website

https://www.eksobionics.com

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.

Executives

Lathan Corinna	director	140 KENDRICK STREET, NEEDHAM MA 02494
Jerome Wong	officer: Interim CFO	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Scott G. Davis	officer: President & COO	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Steven Sherman	director
Jason C Jones	officer: VP of Product Development	EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
John Glenn	officer: Chief Financial Officer	7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
William R Shaw	officer: See Remarks	1414 HARBOUR WAY SOUTH, SUITE 1201, C/O EKSO BIONICS HOLDINGS, INC., RICHMOND CA 94804
Rhonda A. Wallen	director	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Mary Ann Cloyd	director	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Combest Development (hong Kong) Ltd	10 percent owner	ROOM 2210, CC WU BUILDING 302, HENNESSY ROAD, WAN CHAI, HONG KONG K3 999077
Jack Peurach	director, officer: Chief Executive Officer	1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Thomas A Schreck	director	10240 BUBB RD, CUPERTINO CA 95014
Puissance Capital Management (gp) Llc	10 percent owner	950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Theodore T Wang	director, 10 percent owner	C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Christian Babini	officer: VP of Sales, Americas	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1, RICHMOND CA 94804